FDA HCV ‘hold’ pattern continues: Vertex VX-135 hit
This article was originally published in Scrip
Executive Summary
The concern over rising liver enzymes that plagued another experimental hepatitis C virus (HCV) drug earlier this month has now struck Vertex's VX-135 – news that sent the company's shares tumbling 10% in after-hours trading on 25 July.